Six-year summary
|
|
Not adj. pursuant to IFRS |
| Medivir Group 1, sek (000) |
2008 |
2007 |
2006 |
2005 |
2004 |
2003 |
| INCOME STATEMENT |
| Net sales 2 |
91,175 |
249,623 |
126,048 |
102,646 |
82,602 |
149,033 |
| Change in work in progress and finished goods |
0 |
0 |
0 |
0 |
0 |
2,330 |
| Other turnover |
4,800 |
3,840 |
3,287 |
2,211 |
2,505 |
1,252 |
| Operating costs |
-215,708 |
- 290,783 |
- 330,931 |
- 220,996 |
- 211,442 |
- 264,913 |
| Operating profit |
-113,711 |
- 37,320 |
- 201,596 |
- 116,139 |
- 126,335 |
- 112,298 |
| Profit from financial investments 3 |
13,711 |
8,489 |
1,140 |
8,335 |
12,330 |
69,575 |
| Profit after financial items 3 |
-100,023 |
- 28,832 |
- 200,455 |
- 107,805 |
- 114,005 |
- 42,723 |
| Full tax |
820 |
- 487 |
4,876 |
3,229 |
2,490 |
2,409 |
| Profit after full tax |
-99,203 |
- 29,318 |
- 195,580 |
- 104,576 |
- 111,515 |
- 40,314 |
|
08-12-31 |
07-12-31 |
06-12-31 |
05-12-31 |
04-12-31 |
03-12-31 |
| BALANCE SHEET |
| Intangible fixed assets |
482 |
936 |
1,390 |
9,052 |
10,927 |
10,712 |
| Tangible fixed assets |
35,764 |
35,878 |
33,361 |
81,708 |
80,732 |
40,154 |
| Financial fixed assets |
18,793 |
18,793 |
0 |
47 |
47 |
3,130 |
| Inventories and current receivables |
31,990 |
73,928 |
56,942 |
63,304 |
24,323 |
14,518 |
| Liquid assets and short-term investments 4 |
284,486 |
329,330 |
195,066 |
301,875 |
440,569 |
239,174 |
| Shareholders' equity |
287,606 |
383,979 |
186,306 |
377,964 |
475,694 |
277,847 |
| Deferred tax liability / provisions |
0 |
0 |
0 |
2,039 |
2,519 |
0 |
| Long-term liabilities, interest bearing |
0 |
0 |
0 |
11,194 |
21,200 |
3,352 |
| Current liabilities |
83,908 |
74,887 |
100,452 |
66,827 |
59,702 |
26,489 |
| Total assets |
371,515 |
458,866 |
286,758 |
455,985 |
556,597 |
307,688 |
| Capital employed |
287,606 |
383,979 |
193,181 |
398,325 |
506,061 |
281,199 |
1) International Financial Reporting Standards (IFRS) apply for the financial years 2004-2007. Amounts for 2002-2003 are presented pursuant to the accounting principles Medivir applied for the financial year 2004. For a review of the accounting principles applied for the years 2002-2003, refer to the Annual Report 2004.
2) Net sales in 2007 mainly comprised three milestone payments totaling sek 182.3 m for HCV protease inhibitors from Tibotec Pharmaceuticals Ltd.
3) Gains from the divestment of the CCS group were included in financial investments in 2003.
4) The increase in liquid assets in 2007 and 2004 are due to factors including the new share issue effected by Medivir AB in the first quarter of 2007 and the second quarter of 2004.
Key-figures
|
|
Not adj. pursuant to IFRS |
| Medivir group 1 |
2008 |
2007 |
2006 |
2005 |
2004 |
2003 |
| Operating margin, % |
-117.0 |
- 15.0 |
- 159.9 |
- 113.1 |
- 152.9 |
- 75.4 |
| Profit margin, % |
-102.9 |
- 11.6 |
- 159.0 |
- 105.0 |
- 138.0 |
- 28.7 |
| Debt gearing, multiple |
0.0 |
0.00 |
0.04 |
0.05 |
0.06 |
0.0 |
| Return on equity, % |
-29.5 |
- 10.3 |
- 69.3 |
- 24.5 |
- 29.7 |
-13.5 |
| Return on capital employed, % |
-29.6 |
- 9.9 |
- 66.6 |
- 23.7 |
- 28.9 |
- 13.9 |
| Return on total capital, % |
-23.9 |
- 7.6 |
- 52.8 |
- 21.0 |
- 26.2 |
- 12.4 |
| Equity ratio, % |
77.4 |
83.7 |
65.0 |
82.9 |
85.5 |
90.3 |
| Average number of shares, thousand |
20,844 |
16,873 |
12,903 |
12,903 |
10,746 |
8,590 |
| Number of shares, closing balance, thousand |
20,844 |
20,844 |
12,903 |
12,903 |
12,903 |
8,590 |
| Earnings per share, before and after dilution, sek 2 |
-4.76 |
- 1.74 |
- 15.16 |
-8.10 |
- 10.38 |
- 4.69 |
Shareholders' equity per share,
before and after dilution, sek 2 |
13.80 |
18.42 |
14.44 |
29.29 |
36.87 |
32.35 |
| Net worth per share, before and after dilution, sek 2 |
13.80 |
18.42 |
14.44 |
29.29 |
36.87 |
32.96 |
| Cash flow per share after investments, sek |
-2.14 |
- 4.91 |
- 7.39 |
- 2.17 |
- 22.12 |
11.20 |
| Cash flow per share after financing activity, sek |
-2.14 |
7.95 |
- 8.28 |
- 10.75 |
18.74 |
11.10 |
| Dividend per share, sek |
0 |
0 |
0 |
0 |
0 |
0 |
| Number of outstanding warrants |
970,000 |
970,000 |
676,995 |
886,995 |
646,895 |
449,900 |
1) International Financial Reporting Standards (IFRS) apply for the financial years 2004-2007. Amounts for 2002-2003 are presented pursuant to the accounting principles
Medivir applied for the financial year 2004. For a review of the accounting principles applied for the year 2002-2003, refer to the Annual Report 2004.
2) Pursuant to IAS 33, potential ordinary shares do not give rise to any dilution effects when their conversion to ordinary shares implies an improvement to earnings per share, as would apply coincident with the conversion of Medivir's outstanding options.
|
|
